|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TCP1 |
Gene summary for TCP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TCP1 | Gene ID | 6950 |
| Gene name | t-complex 1 | |
| Gene Alias | CCT-alpha | |
| Cytomap | 6q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | E7EQR6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6950 | TCP1 | GSM4909277 | Human | Breast | Precancer | 4.84e-06 | 5.52e-01 | 0.0177 |
| 6950 | TCP1 | GSM4909285 | Human | Breast | IDC | 7.02e-09 | 3.16e-01 | 0.21 |
| 6950 | TCP1 | GSM4909286 | Human | Breast | IDC | 1.72e-03 | 9.92e-03 | 0.1081 |
| 6950 | TCP1 | GSM4909293 | Human | Breast | IDC | 2.28e-02 | -1.72e-01 | 0.1581 |
| 6950 | TCP1 | GSM4909296 | Human | Breast | IDC | 3.13e-19 | -5.37e-01 | 0.1524 |
| 6950 | TCP1 | GSM4909297 | Human | Breast | IDC | 1.43e-17 | -4.55e-01 | 0.1517 |
| 6950 | TCP1 | GSM4909298 | Human | Breast | IDC | 6.92e-05 | -2.70e-01 | 0.1551 |
| 6950 | TCP1 | GSM4909301 | Human | Breast | IDC | 6.07e-11 | -4.10e-01 | 0.1577 |
| 6950 | TCP1 | GSM4909302 | Human | Breast | IDC | 3.62e-15 | -5.13e-01 | 0.1545 |
| 6950 | TCP1 | GSM4909304 | Human | Breast | IDC | 4.33e-05 | -3.20e-01 | 0.1636 |
| 6950 | TCP1 | GSM4909307 | Human | Breast | IDC | 4.02e-09 | -4.13e-01 | 0.1569 |
| 6950 | TCP1 | GSM4909309 | Human | Breast | IDC | 3.59e-12 | -5.17e-01 | 0.0483 |
| 6950 | TCP1 | GSM4909311 | Human | Breast | IDC | 3.18e-34 | -5.70e-01 | 0.1534 |
| 6950 | TCP1 | GSM4909312 | Human | Breast | IDC | 3.93e-09 | -2.61e-01 | 0.1552 |
| 6950 | TCP1 | GSM4909313 | Human | Breast | IDC | 2.15e-04 | -3.56e-01 | 0.0391 |
| 6950 | TCP1 | GSM4909315 | Human | Breast | IDC | 5.62e-05 | -3.45e-01 | 0.21 |
| 6950 | TCP1 | GSM4909319 | Human | Breast | IDC | 8.32e-37 | -6.19e-01 | 0.1563 |
| 6950 | TCP1 | GSM4909320 | Human | Breast | IDC | 2.06e-10 | -5.51e-01 | 0.1575 |
| 6950 | TCP1 | GSM4909321 | Human | Breast | IDC | 1.92e-14 | -3.25e-01 | 0.1559 |
| 6950 | TCP1 | brca1 | Human | Breast | Precancer | 5.45e-03 | 3.08e-01 | -0.0338 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190495121 | Stomach | CSG | positive regulation of establishment of protein localization | 33/1034 | 319/18723 | 4.04e-04 | 6.51e-03 | 33 |
| GO:200027821 | Stomach | CSG | regulation of DNA biosynthetic process | 15/1034 | 106/18723 | 7.08e-04 | 9.89e-03 | 15 |
| GO:005197221 | Stomach | CSG | regulation of telomerase activity | 9/1034 | 47/18723 | 9.41e-04 | 1.23e-02 | 9 |
| GO:005197321 | Stomach | CSG | positive regulation of telomerase activity | 7/1034 | 34/18723 | 2.22e-03 | 2.25e-02 | 7 |
| GO:200057311 | Stomach | CSG | positive regulation of DNA biosynthetic process | 10/1034 | 66/18723 | 3.18e-03 | 2.92e-02 | 10 |
| GO:007020221 | Stomach | CSG | regulation of establishment of protein localization to chromosome | 4/1034 | 12/18723 | 3.20e-03 | 2.92e-02 | 4 |
| GO:190435821 | Stomach | CSG | positive regulation of telomere maintenance via telomere lengthening | 7/1034 | 37/18723 | 3.68e-03 | 3.27e-02 | 7 |
| GO:000700411 | Stomach | CSG | telomere maintenance via telomerase | 10/1034 | 69/18723 | 4.42e-03 | 3.75e-02 | 10 |
| GO:001083311 | Stomach | CSG | telomere maintenance via telomere lengthening | 11/1034 | 81/18723 | 4.83e-03 | 4.03e-02 | 11 |
| GO:007189711 | Stomach | CSG | DNA biosynthetic process | 19/1034 | 180/18723 | 5.12e-03 | 4.17e-02 | 19 |
| GO:19038296 | Stomach | CSG | positive regulation of cellular protein localization | 26/1034 | 276/18723 | 5.64e-03 | 4.50e-02 | 26 |
| GO:19901731 | Stomach | CSG | protein localization to nucleoplasm | 4/1034 | 14/18723 | 5.93e-03 | 4.66e-02 | 4 |
| GO:000645731 | Stomach | CAG | protein folding | 36/552 | 212/18723 | 1.36e-17 | 3.03e-14 | 36 |
| GO:004440331 | Stomach | CAG | biological process involved in symbiotic interaction | 28/552 | 290/18723 | 4.03e-08 | 4.39e-06 | 28 |
| GO:005082131 | Stomach | CAG | protein stabilization | 22/552 | 191/18723 | 5.27e-08 | 5.60e-06 | 22 |
| GO:003164731 | Stomach | CAG | regulation of protein stability | 28/552 | 298/18723 | 7.20e-08 | 7.30e-06 | 28 |
| GO:007259431 | Stomach | CAG | establishment of protein localization to organelle | 33/552 | 422/18723 | 3.87e-07 | 2.98e-05 | 33 |
| GO:190495131 | Stomach | CAG | positive regulation of establishment of protein localization | 25/552 | 319/18723 | 9.63e-06 | 4.05e-04 | 25 |
| GO:005170131 | Stomach | CAG | biological process involved in interaction with host | 18/552 | 203/18723 | 3.40e-05 | 1.12e-03 | 18 |
| GO:200027831 | Stomach | CAG | regulation of DNA biosynthetic process | 12/552 | 106/18723 | 6.78e-05 | 1.89e-03 | 12 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TCP1 | SNV | Missense_Mutation | novel | c.1640N>G | p.Asp547Gly | p.D547G | P17987 | protein_coding | tolerated_low_confidence(0.12) | benign(0.007) | TCGA-A7-A6VW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| TCP1 | deletion | Frame_Shift_Del | c.1430delN | p.Asn477ThrfsTer7 | p.N477Tfs*7 | P17987 | protein_coding | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |||
| TCP1 | SNV | Missense_Mutation | novel | c.1555N>C | p.Glu519Gln | p.E519Q | P17987 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| TCP1 | SNV | Missense_Mutation | novel | c.396N>G | p.Ile132Met | p.I132M | P17987 | protein_coding | tolerated(0.2) | possibly_damaging(0.706) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TCP1 | SNV | Missense_Mutation | c.1438N>T | p.Arg480Cys | p.R480C | P17987 | protein_coding | deleterious(0.02) | possibly_damaging(0.579) | TCGA-A6-A565-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unspecific | 5FU | PD | |
| TCP1 | SNV | Missense_Mutation | c.10N>T | p.Pro4Ser | p.P4S | P17987 | protein_coding | tolerated_low_confidence(0.17) | benign(0) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| TCP1 | SNV | Missense_Mutation | novel | c.501N>A | p.Phe167Leu | p.F167L | P17987 | protein_coding | tolerated(0.26) | benign(0.044) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TCP1 | SNV | Missense_Mutation | rs760874138 | c.1297N>T | p.Arg433Trp | p.R433W | P17987 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CA-5255-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| TCP1 | SNV | Missense_Mutation | c.1064N>T | p.Arg355Ile | p.R355I | P17987 | protein_coding | deleterious(0.03) | possibly_damaging(0.781) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| TCP1 | SNV | Missense_Mutation | novel | c.944N>G | p.Asp315Gly | p.D315G | P17987 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |